The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
: I guess the main one that we've been getting from investors is just what is the disconnect between these improving metrics you're getting in terms
of formulary wins and institutional outreach, et cetera, versus the sort of essentially sort of flat sales performance? And when do we start to see
the correlation between these metrics and the sales performance? And then just as a follow-up to this, can you give any metrics in terms of repeat
orders? And then I have a follow-on up to that. Thanks.
Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
: And then on the repeat orders, can you give any color there?
Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst
: Okay. Great. And then just as we look forward to the Alzheimer's launch, which I think is the focus of everyone, should we expect a similar lag
between these metrics and the sales performance? Or because you'll be so established at that point, do you expect sort of a much greater correlation
and more rapid uptake. Thank you.
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Actually all around SERENITY. So the first one, in the at-home use context, how can we tune them is the company to an important fact that in 2015,
the FDA approved oral mucosal gel, for at-home use for in dogs and (inaudible) at a strength of 90 micrograms per mil and do you expect an
advisory committee meeting for use.
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Got it. And then for SERENITY III, how do you approach a scenario where the 60 micrograms strength does not have a statistically significant score
and efficacy, but is otherwise safe. I'm asking because the Phase Ib/II study did not hit significance for the 60-microgram dose when you announced
the results in July 2019.
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: And I'll stop a commercial question and a quick one. What time of the year do the bulk of the IDN votes happened?
| 
